Featured Research

from universities, journals, and other organizations

First Method For Testing, Assessing Drug Treatments For Chagas' Disease Identified

Date:
April 22, 2008
Source:
University of Georgia
Summary:
Scientists have identified for the first time a sensitive method for testing and assessing the efficacy of treatments for Chagas' disease. The study could lead to new treatments for long-term sufferers of a disease that can be fatal.

Chagas' disease is a tropical parasitic sickness that currently affects more than 16 million people, with a staggering 100 million at risk, largely in the tropical areas of South and Central America. And yet the main drug used to treat the disease is highly toxic and causes serious side effects.

Now, new research just published by scientists at the University of Georgia has identified for the first time a sensitive method for testing and assessing the efficacy of treatments for Chagas' disease. The study could lead to new treatments for long-term sufferers of a disease that can be fatal.

"It is the first time we've been able to identify a set of measurements to determine whether or not a drug for Chagas actually works," said Rick Tarleton, distinguished research professor of cellular biology and a faculty member at UGA's Center for Tropical and Emerging Global Diseases.

The research was published today in the online edition of the journal Nature Medicine. Co-authors, also from the University of Georgia, are postdoctoral associate Juan Bustamante and master's degree student Lisa Bixby.

The research presents the first and only evidence that the current drug therapies for Chagas' disease can actually completely cure the infection. Still, current treatments have potentially severe side effects and are thought to be effective in less than 50 percent of those treated. More important, the model the team developed can be used for the development of better drugs against Trypanosoma cruzi, the parasite that causes the disease.

"We also found that the immunological markers of cure in this system, which we developed in mice, provide a means to monitor drug treatment efficacy in humans, something that has been the biggest impediment to developing new drugs," said Tarleton.

There's a fourth finding more important to the big picture of immunology, however. This study shows that chronic infections do not by default exhaust the immune system.

"Current dogma on chronic infections is that constant stimulation of the immune system eventually wears it out, which is one of the problems in treating such disorders as HIV/AIDS," said Tarleton. "This study shows that one can have an infection for more than a year, but, when cured, the immune system develops a stable, protective memory."

This idea of "memory" is at the heart of the study, and it involves T-cells, specifically one kind called cytotoxic or "killer" T-cells, which are blood-borne white blood cells that destroy T. cruzi-infected cells in the case of Chagas' disease and virally infected and tumor cells in other cases. Tarleton and his colleagues documented the development of stable killer T-cell "memory" following drug-induced cure of a chronic infection. In other words, when the body is cleared of parasites, the killer T-cells, which may have been "exhausted" by battling the persistent infection, bounce back and recall how to do their job.

The implications of the study could be considerable, Tarleton said. The T. cruzi parasite is passed to humans from the bite of blood-sucking assassin bugs, which go by many names, including "kissing bugs." The infection can also be acquired through contaminated blood transfusions and by eating food contaminated with parasites.

In its first stages, the disease often causes no more than a local swelling at the point of the bite. This acute phase often passes, but the malady, if untreated, can then enter a chronic phase that can last for decades and cause heart disease and intestinal disorders. In many cases, Chagas', named for the Brazilian scientist who first described it nearly a century ago, is fatal.

While several hundred thousand people in the United States may have the disease, these are largely immigrants from Latin American countries. The disease, however, is a major public health issue in all of South America and kills as many as 50,000 people each year, according to some estimates, making it the most significant parasitic disease of the Americas, Tarleton said.

The research was supported by grants from the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of Georgia. Note: Materials may be edited for content and length.


Cite This Page:

University of Georgia. "First Method For Testing, Assessing Drug Treatments For Chagas' Disease Identified." ScienceDaily. ScienceDaily, 22 April 2008. <www.sciencedaily.com/releases/2008/04/080420151756.htm>.
University of Georgia. (2008, April 22). First Method For Testing, Assessing Drug Treatments For Chagas' Disease Identified. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2008/04/080420151756.htm
University of Georgia. "First Method For Testing, Assessing Drug Treatments For Chagas' Disease Identified." ScienceDaily. www.sciencedaily.com/releases/2008/04/080420151756.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins